Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing Organization
Nottingham, U.K., 14 November 2017: Quotient Sciences (“Quotient”), the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading,
Pharmaterials has a significant track record in supporting the development of small molecule drug products for oral and inhaled delivery. The company’s portfolio of services spans the characterization and optimization of drug substance physical forms, the development of preclinical and clinical formulations, through to clinical trial manufacturing and subsequent global drug product supply. The business was founded in 2000 and is located in a 48,000-square feet facility that houses 13 GMP manufacturing suites, with space for future expansion.
With over 700 employees, six operating sites across the U.S. and U.K. and a 30-year track record for quality services, Quotient is focused on delivering an innovative portfolio of services that are proven to shorten development timelines, reduce associated costs and accelerate the delivery of new medicines to patients globally.
For further information, please contact:
Tel: +44 (0)115 931 5102